Roivant Sciences launched the new subsidiary Hemavant, which hit the ground running with a licensing agreement from Eisai for RVT-2001, a potential first-in-class small molecule SF3B1 modulator.
OpGen Subsidiary Ares Genetics Launches AREScloud AREScloud is a new, commercial web application aimed at accelerating the analysis of sequenced clinical isolates AREScloud offers an advanced solution […]
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech Inc. launched subsidiary Jeune Inc. to promote gene therapies for aesthetic skin conditions.
Pharmacosmos Therapeutics Inc. was established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric for iron deficiency anemia (IDA) patients in the United States.
Civica Rx and 18 independent Blue Cross and Blue Shield (BCBS) companies formed a new subsidiary dedicated to lowering the cost of select generic drugs.
IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.